Muntinlupa suspends Sinovac second dose jab due to delay in arrival of new supply
The Muntinlupa City government announced that it will suspend the vaccination of second dose recipients of Sinovac Life Sciences’ CoronaVac vaccine due to the expected delay in the arrival of new supply in the country.

The city government made the decision after it was advised by the National Task Force Against COVID-19, which is headed by Sec. Carlito Galvez Jr., about the delay in the arrival of new Sinovac vaccines in the country.
In a notice issued Saturday, the Muntinlupa City COVID-19 Vaccination Program (MunCoVac) said “based on Advisory No. 62 of the National Task Force Against COVID-19, there will be a delay in the delivery of Sinovac in the country.”
“Because of this, the vaccination of those scheduled to receive the second dose of Sinovac will be postponed in all vaccination sites starting July 12 until a new batch of supply from the national government arrives,” said MunCoVac.
The Sinovac second dose vaccination at Festival Mall and SM Center Muntinlupa will be suspended starting July 13.
“When a new (vaccine) allocation arrives, the priority in the vaccination are those whose second dose jab schedules have been adjusted so make sure that you go when there is a new schedule that will be sent via text message,” added MunCoVac.
It said that according to the Department of Health, the second dose can be administered until three to six months from the time the first dose was administered.
MunCoVac clarified that those who will receive the second dose of the Pfizer-BioNTech vaccine will not be affected by the advisory as only Sinovac recipients are covered by the suspension.
Last July 5, MunCoVac announced the suspension of first dose vaccination for two weeks due to inadequate vaccine supply.
As of July 9, 218,064 doses have been administered in Muntinlupa. Of the total, 152,900 individuals received their first dose, or 39.6 percent of the target population of 385,725.
In addition, 65,164 individuals are now fully vaccinated after getting their second dose, or 16.9 percent of the target population.